Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telaglenastat - Cornerstone Pharmaceuticals

Drug Profile

Telaglenastat - Cornerstone Pharmaceuticals

Alternative Names: CB 839

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Calithera Biosciences
  • Developer Calithera Biosciences; Case Western Reserve University; Cornerstone Pharmaceuticals Inc; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer
  • Class Acetamides; Antineoplastics; Ethers; Fluorinated hydrocarbons; Pyridazines; Pyridines; Small molecules; Thiadiazoles
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Chronic obstructive pulmonary disease
  • Discontinued Colorectal cancer; Glioma; Haematological malignancies; Leukaemia; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 08 Mar 2024 National Cancer Institute reinitiates a phase I trial for non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT04250545)
  • 11 Sep 2023 Preclinical trials in Cancer in USA (PO), prior to September 2023 (Cornerstone Pharmaceuticals, Inc pipeline, September 2023)
  • 09 Sep 2023 Preclinical trials in Chronic obstructive pulmonary disease in USA (Intranasal) before September 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top